Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 12 2026

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has announced the launch of AI-powered Continuous Glucose Monitors, DiasensTM and GlucoLiveTM, expanding its companion diagnostics portfolio. These devices are designed for patients with diabetes, Chronic Kidney Disease, and those who have undergone transplants, providing continuous glycaemic monitoring and integrated remote care. The launch aims to enhance patient convenience and improve quality of life by offering real-time glucose data and analytics through a dedicated mobile application.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 12, 2026, titled "Zydus expands companion diagnostics portfolio with the launch of AI-powered Continuous Glucose Monitor DiasensTM and GlucoLiveTM".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases